Precision BioSciences Inc (DTIL)vsRegeneron Pharmaceuticals Inc (REGN)
DTIL
Precision BioSciences Inc
$7.88
+1.40%
HEALTHCARE · Cap: $204.35M
REGN
Regeneron Pharmaceuticals Inc
$624.72
+0.19%
HEALTHCARE · Cap: $66.35B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 33001% more annual revenue ($14.92B vs $45.07M). REGN leads profitability with a 29.6% profit margin vs -96.7%. REGN earns a higher WallStSmart Score of 64/100 (C+).
DTIL
Avoid33
out of 100
Grade: F
REGN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+72.2%
Fair Value
$14.65
Current Price
$7.88
$6.77 discount
Margin of Safety
+53.0%
Fair Value
$1346.63
Current Price
$624.72
$721.91 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 37272.0% year-over-year
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 30 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -58.5% — below average capital efficiency
Weak financial health signals
Earnings declined 7.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : DTIL
The strongest argument for DTIL centers on Revenue Growth, Price/Book. Revenue growth of 37272.0% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 29.6% and operating margin at 20.7%. Revenue growth of 19.0% demonstrates continued momentum.
Bear Case : DTIL
The primary concerns for DTIL are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
DTIL profiles as a hypergrowth stock while REGN is a growth play — different risk/reward profiles.
DTIL carries more volatility with a beta of 1.28 — expect wider price swings.
DTIL is growing revenue faster at 37272.0% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (64/100 vs 33/100), backed by strong 29.6% margins and 19.0% revenue growth. DTIL offers better value entry with a 72.2% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Precision BioSciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company is headquartered in Durham, North Carolina.
Visit Website →Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?